The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

PR Newswire
May 18, 2023 — 21:23 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: biotech Chengdu China coronavirus Covid-19 Education guangdong Guangzhou healthcare Pandemic procurement Sichuan state council University Vaccine

Related News:

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024

August 27, 2024 — 11:00

Docquity and Vietnam Association of Preventive Medicine (VAPM) Partner to Advance Medical Training

August 21, 2024 — 10:00

2024 World Life Science Conference Scheduled for October 19 in Hainan, China

August 18, 2024 — 20:20

PRA Group Leader Wins Silver Stevie Award in 2024 International Business Awards

August 16, 2024 — 06:31

17sing’s 9th Anniversary Celebration, tens of millions of users celebrate together

July 20, 2024 — 11:42

Franchising and Licensing Asia (FLAsia) 2024